Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2012 Nov;11(11):860-72. doi: 10.1038/nrd3864. Epub 2012 Oct 19.

MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles.

Author information

1
miRagen Therapeutics, 6200 Lookout Rd, Boulder, Colorado 80301, USA.

Abstract

In recent years, prominent roles for microRNAs (miRNAs) have been uncovered in several cardiovascular disorders. The ability to therapeutically manipulate miRNA expression and function through systemic or local delivery of miRNA inhibitors, referred to as antimiRs, has triggered enthusiasm for miRNAs as novel therapeutic targets. Here, we focus on the pharmacokinetic and pharmacodynamic properties of current antimiR designs and their relevance to cardiovascular indications, and evaluate the opportunities and obstacles associated with this new therapeutic modality.

PMID:
23080337
DOI:
10.1038/nrd3864
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center